Molecular mimicry of NMDA receptors may contribute to neuropsychiatric symptoms in severe COVID-19 cases

Abstract Approximately 30% of individuals with severe SARS-CoV-2 infections also develop neurological and psychiatric complaints. In rare cases, the occurrence of autoimmune encephalitis has been reported after SARS-CoV-2 infection. In this systematic review, we have identified eight SARS-CoV-2-asso...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Veronika Vasilevska, Paul C. Guest, Hans-Gert Bernstein, Matthias L. Schroeter, Christian Geis, Johann Steiner
التنسيق: مقال
اللغة:English
منشور في: BMC 2021-10-01
سلاسل:Journal of Neuroinflammation
الموضوعات:
الوصول للمادة أونلاين:https://doi.org/10.1186/s12974-021-02293-x
الوصف
الملخص:Abstract Approximately 30% of individuals with severe SARS-CoV-2 infections also develop neurological and psychiatric complaints. In rare cases, the occurrence of autoimmune encephalitis has been reported after SARS-CoV-2 infection. In this systematic review, we have identified eight SARS-CoV-2-associated cases of anti-NMDA receptor encephalitis. All had cerebrospinal fluid antibodies against the NMDA receptor and a recent onset of working memory deficits, altered mental status, or psychiatric symptoms, such as confusion, agitation, auditory hallucination, catatonia and speech dysfunction. All patients received high-dose steroid and immunoglobulin therapeutics and conditions improved in each case. These findings suggest that clinical attention should be paid to warning signs of autoimmune encephalitis in severe COVID-19 cases. If characteristic features of autoimmune encephalitis are present, autoantibody diagnostics should be performed and confirmed cases should be treated with immunotherapy to minimize neurological impairments.
تدمد:1742-2094